Regulatory & NPN
Verified as at 23 September 2026
The short answer
Every natural health product sold in Canada needs a product licence before it can be marketed. You submit product details to Health Canada's Natural and Non-prescription Health Products Directorate, and once the application is assessed and authorised the product receives an eight-digit NPN that must appear on the label. Most delays come from the application itself rather than the review queue: unsupported claims, ingredients that fall outside a monograph, missing specifications, or a label that does not match what was submitted.
Who this article is for
Founders preparing a first Canadian launch, product developers scoping a new SKU, regulatory and quality managers assembling a submission, and US or international brands adding Canada to their roadmap.
Key takeaways
A product licence is required before marketing, not after. The NPN must be on the label at the point of sale.
Whether your ingredients and claims fit an existing Health Canada monograph is the single biggest driver of how straightforward your application will be.
Product licensing and site licensing are separate. Manufacturers, packagers, labellers and importers need their own site licence.
Claims drive evidence. A claim outside a monograph needs supporting evidence submitted with the application.
Finalise the formula, dose and claims before artwork. Label changes after submission are a common source of rework.
What a product licence actually authorises
Health Canada requires a product licence for every natural health product sold in Canada. The application describes the product in specific terms: medicinal ingredients, their source, potency, non-medicinal ingredients, and the recommended use. Once the application is assessed and market authorisation is granted, the product carries an eight-digit number preceded by NPN, or DIN-HM for a homeopathic medicine. Health Canada’s product licensing overview sets out the information required.
The practical consequence is that the licence is tied to a specific product as described. If the formula, dose, format or claims change materially after authorisation, that change has to be reflected through the appropriate amendment process rather than applied quietly at the factory.
Monograph route or evidence route
The first question to answer is whether your ingredients, doses and intended claims align with an existing Health Canada monograph. Monographs describe pre-assessed combinations of ingredient, dose, duration of use and permitted claim language. Staying inside a monograph is the most predictable route. Stepping outside it — a higher dose, a novel ingredient, a claim that is not listed — shifts the burden onto you to submit supporting evidence. Start with the Compendium of Monographs and check each ingredient against it before the formula is locked.
It is also worth checking the Licensed Natural Health Products Database to see how comparable products have been licensed. It will not tell you what will be approved, but it shows you the shape of what already has been.
Site licensing is a separate obligation
A product licence covers the product. It does not cover the operations behind it. Sites that manufacture, package, label or import natural health products for sale in Canada need their own site licence. For international brands this is often the surprise: your contract manufacturer abroad may be perfectly capable, but the Canadian importer still carries obligations, and evidence of good manufacturing practices has to exist in a form that can be produced on request.
Where applications actually lose time
In our experience the delays that hurt most are self-inflicted and preventable. The recurring patterns look like this:
Claims written by marketing before regulatory review. A claim that sits outside the monograph turns a straightforward filing into an evidence submission.
Incomplete ingredient detail. Source organism, part used, extract ratio and solvent matter. A supplier specification sheet is not always enough on its own.
Dose stated per serving rather than per dosage unit, or a recommended use that does not match the dose actually delivered.
Risk information that is missing or inconsistent with the monograph: cautions, contraindications, known adverse reactions.
Artwork printed against a draft. When the label and the submission diverge, one of them has to change.
Responses to Health Canada requests for information handled slowly or partially, which extends the exchange unnecessarily.
A worked example
A brand brings a magnesium and L-theanine capsule to market. Both ingredients are well established, and on paper the filing looks simple. The complication is the positioning: the packaging concept promises help falling asleep. Once the claim is compared against the monograph language available for those ingredients at the intended doses, the options become concrete. Adjust the claim to what the monograph supports, change the formula so a stronger claim is available, or prepare evidence for the claim as written. All three are legitimate. Only one of them is cheap, and it is much cheaper before the artwork is printed.
On timelines
Review timelines vary by application type and by how complete the submission is, and published service standards change. Rather than plan against a number you read once, confirm the current expectations on Health Canada’s own pages when you build your schedule, and treat any request for information as the real variable. The applications that move fastest are the ones that arrive complete.
What to prepare
Final formula with each medicinal ingredient, source organism, part used, extract ratio and quantity per dosage unit
Full non-medicinal ingredient list with function for each
Monograph check completed for every ingredient at the intended dose
Intended claims written out and matched to monograph language, or evidence assembled where they are not
Recommended use, dose, duration of use and directions consistent with the formula
Risk information: cautions, warnings, contraindications, known adverse reactions
Specifications and finished product testing approach, including identity and purity
Site licence status confirmed for manufacturer, packager, labeller and importer
Bilingual label copy drafted, with artwork held until the submission is stable
Frequently asked
Can I sell in Canada while my application is under review?
No. A natural health product requires a product licence before it is marketed in Canada, and the NPN has to appear on the label.
Does a US facility need anything for a Canadian launch?
The product needs a licence, and the sites involved in manufacturing, packaging, labelling and importing for the Canadian market need site licensing. Confirm who holds which obligation early, because it affects contracts and documentation.
What happens if Health Canada asks for more information?
You receive a request and respond within the stated period. Complete, well-organised responses shorten the exchange. Partial answers usually invite another round.
Do I need clinical trials to support my claims?
Not necessarily. Where your ingredients and doses fit an existing monograph, the claim language available there is already pre-assessed. Evidence requirements arise when you go beyond that.
Next step
General guidance only goes so far. Send us the formula, the label, the request or the market, and we will tell you what we would do next.
Review My NPN Pathway